Massive Bio

Massive Bio is a leading health-tech company dedicated to transforming the way cancer patients access clinical trials. Operating across 17 countries in North America, Europe, and LATAM, Massive Bio leverages proprietary AI technology to connect patients with the most suitable clinical trials, irrespective of their location, income, or cancer type. Massive Bio collaborates with pharmaceutical companies, CROs, and healthcare institutions to expedite oncology trial enrollment, decrease dropout rates, and provide real-world evidence. The company is committed to simplifying trial access and optimizing recruitment throughout the oncology ecosystem.

Massive Bio is headquartered in Istanbul, TR and has established itself as a key player in the healthcare sector since its founding in 2014. With a strong focus on targeted cancer therapies, cancer genomics, and tumor profiling technologies, Massive Bio continues to innovate and expand its reach. The company’s commitment to precision oncology and personalized cancer treatment options ensures that patients receive the best possible care and access to cutting-edge research.

With over 160,000 patients onboarded and partnerships with more than 45 pharmaceutical and CRO clients, Massive Bio is a trusted name in cancer care. The company’s dedication to improving patient outcomes and accelerating cancer research makes it a valuable asset to the healthcare community. Massive Bio is always striving to enhance its offerings and broaden its impact on the oncology landscape.

To the manager of Massive Bio: We invite you to create a customized and exclusive company showcase and product listing on our platform, providing you with enhanced visibility and opportunities for further growth.